CRISPR is capable of more than we initially expected | Jennifer Doudna

Summary

Jennifer Doudna describes CRISPR as a discovery that began with curiosity-driven research into a microbial defense system and became a programmable genome-editing technology. She emphasizes its potential—from treating disease to changing organisms relevant to climate and agriculture—as well as the need to manage its risks responsibly.

How CRISPR works and how the breakthrough happened

• CRISPR stands for Clustered Regularly Interspaced Short Palindromic Repeats. It evolved in microbes as a defense against infection.
• Doudna compares genome editing to using a word processor to change letters in the “code of life.”
• Research by Doudna and Emmanuelle Charpentier identified how the protein Cas9 works with a guide RNA:
  1. The guide RNA acts as a molecular “zip code,” directing Cas9 to a matching DNA sequence.
  2. Cas9 cuts the DNA at that location.
  3. The cell’s response to the cut can produce a genetic change at the targeted site.
• Because the guide RNA can be reprogrammed, the system can be directed to selected DNA sequences in different organisms.
• Doudna credits the discovery to early observations of CRISPR in bacteria, work by researchers in her laboratory, collaboration across laboratories, and sustained investigation of the system’s biology and chemistry.

Medical applications and access

• A CRISPR-based therapy for sickle cell disease has received FDA approval. The treatment edits a patient’s cells outside the body and returns them to the patient.
• Doudna describes the therapy as a one-time treatment that appears to provide a functional cure for some patients. Sickle cell disease can involve recurring severe health problems and hospitalizations.
• The treatment currently costs around $2 million and requires cell extraction, laboratory editing, transfusion, hospitalization, and long-term follow-up.
• Lowering costs and expanding access will require technical and manufacturing improvements, as well as attention to regulatory processes. Doudna notes that scaling treatments for large numbers of patients is beyond the usual role of academic laboratories and requires companies and other partners.
• Another major advance would be reliable ways to deliver CRISPR components into many kinds of cells. Doudna expects a toolbox of delivery approaches rather than a single solution.

Climate and agriculture

• CRISPR may help reduce methane emissions by changing microbes in cattle and rice-growing environments that produce methane, a powerful greenhouse gas.
• The goal is to alter microbial metabolism so that carbon is used to produce other substances instead of methane.
• More broadly, genome editing could be applied to microbes, plants, insects, and other organisms involved in agriculture. Potential aims include developing more productive or nutritious crops and addressing climate-related challenges.
• Doudna argues that CRISPR can make some changes more quickly and precisely than traditional breeding or microbial manipulation.

Ethics, risks, and uses beyond medicine

• The 2018 announcement that embryos had been edited to produce “CRISPR babies” shocked many people and highlighted the need for international oversight, particularly for human germline editing, which can affect future generations.
• Doudna says ethical review must continue as the technology advances; it cannot be treated as a completed task.
• Gene drives are a potential environmental application in which an engineered trait can spread quickly through a population, such as mosquitoes. They might help address mosquito-borne diseases, but could also spread undesirably or disrupt ecosystems.
• Recreating extinct organisms using genome editing is technically intriguing and attracts attention and investment. Doudna regards practical de-extinction—such as bringing back woolly mammoths—as unlikely in the near term, while some proposals involving extinct animals or plants remain speculative or niche.
• She compares CRISPR with AI as powerful technologies that may bring benefits but also cause harm. In her view, CRISPR benefited from earlier biotechnology safety frameworks developed around molecular cloning. AI faces a harder regulatory challenge, in part because of competitive pressure to move quickly.

AI, experimentation, and scientific practice

• AI is already helping biological research by summarizing projects, organizing and converting data, combining datasets, and writing code.
• Machine-learning systems can search large datasets for patterns that may be difficult for people to detect. They may increasingly help researchers make predictions and generate hypotheses.
• Doudna expects AI to accelerate research and help scientists choose which experiments are worth doing. She stresses that useful AI in biology still depends on human scientific judgment.
• She does not expect scientists to become merely desk-based workers in the near future. Lab work often requires flexible, on-the-spot changes that are easy for a person but difficult for current robots.
• She imagines researchers using AI agents as technical assistants, while scientists remain responsible for interpreting project details and deciding what experiments to pursue.

Science funding and the future

• Doudna distinguishes among academic research, biotechnology companies, and established pharmaceutical companies. Academic research can explore questions without the same product deadlines as companies, while companies can assemble teams and develop applications at scale.
• She argues that public support for fundamental, curiosity-driven research is essential because breakthroughs can arise unexpectedly. She cites CRISPR, COVID vaccines, and cancer immunotherapies as examples of advances built on foundational research.
• She sees major future opportunities in using science to address human health and environmental challenges, and encourages scientists in training to help pursue them.

Researchers and sources featured

Researchers

• Jennifer Doudna
• Emmanuelle Charpentier
• Blake Wiedenheft
• Jillian Banfield

Organizations and other named sources

• Innovative Genomics Institute
• U.S. Food and Drug Administration (FDA)
• World Health Organization
• UNESCO
• National Academies of Science
• Michael Crichton
• Jurassic Park (novel and film)